Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Vertex Pharmaceuticals Inc Reiterates FY 2013 Revenue Guidance


Tuesday, 30 Apr 2013 04:02pm EDT 

Vertex Pharmaceuticals Inc reiterated financial guidance for fiscal 2013 total revenues to be in the range of $1.10 billion to $1.25 billion. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $1.17 billion for fiscal 2013. 

Company Quote

35.08
-0.09 -0.26%
24 Dec 2014